Targeted bone marrow radioablation with 153Samarium-Lexidronam promotes allogeneic hematopoietic chimerism and donor-specific immunologic hyporesponsiveness

Transplantation

Volumn 77, Issue 5, 2004, Pages 647-655

  Inverardi, Luca ^a   Linetsky, Elina ^a   Pileggi, Antonello ^a   Molano, R Damaris ^a   Serafini, Aldo ^a   Paganelli, Giovanni ^b   Ricordi, Camillo ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Istituto di Oncologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 LIGAND MONOCLONAL ANTIBODY; LEXIDRONAM SAMARIUM SM 153; SAMARIUM 153; T LYMPHOCYTE RECEPTOR BETA CHAIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; BONE MARROW DEPRESSION; CHIMERA; CONTROLLED STUDY; FLOW CYTOMETRY; GRAFT SURVIVAL; HEMATOLOGIC MALIGNANCY; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOPHENOTYPING; IRRADIATION; LYMPHOCYTE COUNT; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SKIN GRAFT; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL LINEAGE; GRAFT SURVIVAL; IMMUNE TOLERANCE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MYELOABLATIVE AGONISTS; ORGANOMETALLIC COMPOUNDS; ORGANOPHOSPHORUS COMPOUNDS; SKIN TRANSPLANTATION; TRANSPLANTATION CHIMERA;

EID: 1642407010     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000112436.26473.A2     Document Type: Article

References (34)

1. Saba N, Flaig T. Bone marrow transplantation for nonmalignant diseases. J Hematother Stem Cell Res 2002; 11: 377.
2. Furst DE. Stem cell transplantation for autoimmune disease: progress and problems. Curr Opin Rheumatol 2002; 14: 220.
3. Oyama Y, Papadopoulos EB, Miranda M, et al. Allogeneic stem cell transplantation for Evans syndrome. Bone Marrow Transplant 2001; 28: 903.
4. Pratt G, Kinsey SE. Remission of severe, intractable autoimmune haemolytic anaemia following matched unrelated donor transplantation. Bone Marrow Transplant 2001; 28: 791.
5. Berdeja JG, Flinn IW. New approaches to blood and marrow transplantation for patients with low-grade lymphomas. Curr Opin Oncol 2001; 13: 335.
6. Chilton PM, Huang Y, Ildstad ST. Bone marrow cell graft engineering: from bench to bedside. Leuk Lymphoma 2001; 41: 19.
7. Burt RK, Slavin S, Burns WH, et al. Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood 2002; 99: 768.
8. Inverardi L, Ricordi C. Tolerance and pancreatic islet transplantation. Philos Trans R Soc Lond Biol Sci 2001; 356: 759.
9. Waldmann H. Therapeutic approaches for transplantation. Curr Opin Immunol 2001; 13: 606.
10. Sykes M, Sachs DH. Mixed chimerism. Philos Trans R Soc Lond B Biol Sci 2001; 356: 707.
11. Mayumi H, Good RA. Induction of tolerance across major barriers using a two-step method with genetic analysis of tolerance induction. Immunobiology 1989; 179: 86.
12. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature 1984; 307: 168.
13. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989; 169: 493.
14. Colson YL, Li H, Boggs SS, et al. Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J Immunol 1996; 157: 2820.
15. Durham MM, Bingaman AW, Adams AB, et al. Cutting edge: administration of anti-CD40 ligand and donor bone marrow leads to hemopoietic chimerism and donor-specific tolerance without cytoreductive conditioning. J Immunol 2000; 165: 1.
16. Pearson TC, Alexander DZ, Hebdrix R, et al. CTLA4-Ig plus bone marrow induces long-term allograft survival and donor specific unresponsiveness in the murine model. Evidence for hematopoietic chimerism. Transplantation 1996; 61: 997.
17. Seung E, Iwakoshi N, Woda BA, et al. Allogeneic hematopoietic chimerism in mice treated with sublethal myeloablation and anti-CD154 antibody: absence of graft-versus-host disease, induction of skin allograft tolerance, and prevention of recurrent autoimmunity in islet-allografted NOD/Lt mice. Blood 2000; 95: 2175.
18. Wekerle T, Kurtz J, Ito H, et al. Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat Med 2000; 6: 464.
19. Wekerle T, Sayegh MH, Ito H, et al. Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and tolerance. Transplantation 1999; 68: 1348.
20. Sharabi Y, Abraham VS, Sykes M, et al. Mixed allogeneic chimeras prepared by a non-myeloablative regimen: requirement for chimerism to maintain tolerance. Bone Marrow Transplant 1992; 9: 191.
21. Wekerle T, Nicolic B, Pearson DA, et al. Minimal conditioning required in a murine model of T cell depletion, thymic irradiation and high-dose bone marrow transplantation for the induction of mixed chimerism and tolerance. Transpl Int 2002; 15: 248-253.
22. Hale DA, Gottschalk R, Umemura A, et al. Establishment of stable multilineage hematopoietic chimerism and donor-specific tolerance without irradiation. Transplantation 2000; 69: 1242-1251.
23. Goeckeler WF, Edwards B, Volkert WA, et al. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 1987; 28: 495.
24. 153Sm-EDTMP and melphalan chemoradiotherapy regimen for bone marrow ablation prior to marrow transplantation: an experimental model in the rat. Nucl Med Commun 1992; 13: 321.
25. Serafini AN. Systemic metabolic radiotherapy with samarium-153 EDTMP for the treatment of painful bone metastasis. Q J Nucl Med 2001; 45: 91.
26. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 1998; 16: 1574.
27. Farhanghi M, Holmes RA, Volkert WA, et al. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med 1992; 33: 1451.
28. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 1993; 34: 1839.
29. Sykes M, Szot GL, Swenson KA, et al. Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997; 3: 783.
30. Wekerle T, Sayegh MH, Hill J, et al. Extrathymic T cell deletion and allogeneic stem cells engraftment induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 1998; 187: 2037.
31. Lee TH, Reed W, Mangawang-Montalvo L, et al. Donor WBCs can persist and transiently mediate immunologic function in a murine transfusion model: effects of irradiation, storage, and histocompatibility. Transfusion 2001; 41; 637.
32. Rosengard BR, Kortz EO, Ojikutu CA, et al. The failure of skin grafting to break tolerance to class I-disparate renal allografts in miniature swine despite inducing marked antidonor cellular immunity. Transplantation 1991; 52(6): 1044-1052.
33. Gorczynski RM, Holmes W. Specific manipulation in vivo of immunity to skin grafts bearing minor histocompatibility differences. Immunol Lett 1991; 27(2): 163-171.
34. Pierce GE. Allogeneic versus semiallogeneic F1 bone marrow transplantation into sublethally irradiated MHC-disparate hosts. Effects on mix lymphoid chimerism, skin graft tolerance, host survival, and alloreactivity. Transplantation 1990; 49(1): 138-144.